BiotechTV’s Brad Loncar interviews A. Katopodis on ways to solve T-cell exhaustion
For the full story, please, check out this link to Biotech TV and to find out more about Brad find him on LinkedIn.
Latest News
01.04.2025
Immuno-Oncology Progress: PragmaTIL Trial Receives Approval, with Anaveon as a Key Partner
As a key partner, we are proud to announce that PragmaTIL has received regulatory approval to launch its clinical trial, bringing safer and more effective cell therapy one step closer to cancer patients. 🔬 The trial will start at VHIO (Spain) and Herlev Hospital (Denmark),…Read more
18.12.2024
Anaveon appoints Dr. Richard Sachse as Chief Medical Officer
Basel, December 18, 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective February 1, 2025. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and…Read more
07.11.2024
Anaveon presents new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Basel, Novmeber 9, 2024 – Anaveon, a clinical stage, immuno-oncology company, presents posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas. Abstracts will…Read more
Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com